German, Austrian, and Swiss Guidelines for Systemic Treatment of Gastric Cancer

Overview

Journal Gastric Cancer

Specialties Gastroenterology
Oncology

Date 2023 Oct 17

PMID 37847333

Authors

Florian Lordick

Salah-Eddin Al-Batran

Dirk Arnold

Markus Borner

Christiane J Bruns

Wolfgang Eisterer

Gerhard Faber

Ines Gockel

Dieter Koberle

Sylvie Lorenzen

Markus Mohler

Ron Pritzkuleit

Michael Stahl

Peter Thuss-Patience

Ewald Woll

Thomas Zander

Georg Maschmeyer

Affiliations

Soon will be listed here.

Abstract

The updated edition of the German, Austrian and Swiss Guidelines for Systemic Treatment of Gastric Cancer was completed in August 2023, incorporating new evidence that emerged after publication of the previous edition. It consists of a text-based "Diagnosis" part and a "Therapy" part including recommendations and treatment algorithms. The treatment part includes a comprehensive description regarding perioperative and palliative systemic therapy for gastric cancer and summarizes recommended standard of care for surgery and endoscopic resection. The guidelines are based on a literature search and evaluation by a multidisciplinary panel of experts nominated by the hematology and oncology scientific societies of the three involved countries.

References

LAUREN P . THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. Acta Pathol Microbiol Scand. 1965; 64:31-49. DOI: 10.1111/apm.1965.64.1.31. View

Parsonnet J, Vandersteen D, Goates J, Sibley R, Pritikin J, Chang Y . Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. J Natl Cancer Inst. 1991; 83(9):640-3. DOI: 10.1093/jnci/83.9.640. View

Al-Batran S, Hartmann J, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R . Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008; 26(9):1435-42. DOI: 10.1200/JCO.2007.13.9378. View

Chen C, Hsu J, Wu D, Kang W, Hsieh J, Jaw T . Gastric cancer: preoperative local staging with 3D multi-detector row CT--correlation with surgical and histopathologic results. Radiology. 2007; 242(2):472-82. DOI: 10.1148/radiol.2422051557. View

Kwee R, Kwee T . Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009; 12(1):6-22. DOI: 10.1007/s10120-008-0492-5. View

Catalano M, Sivak Jr M, Rice T, Gragg L, van Dam J . Endosonographic features predictive of lymph node metastasis. Gastrointest Endosc. 1994; 40(4):442-6. DOI: 10.1016/s0016-5107(94)70206-3. View

Tada M, Tanaka Y, Matsuo N, Shimamura T, Yamaguchi K . Mucosectomy for gastric cancer: current status in Japan. J Gastroenterol Hepatol. 2000; 15 Suppl:D98-102. DOI: 10.1046/j.1440-1746.2000.02137.x. View

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

Ychou M, Boige V, Pignon J, Conroy T, Bouche O, Lebreton G . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29(13):1715-21. DOI: 10.1200/JCO.2010.33.0597. View

10.

Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma.... Lancet. 2019; 393(10184):1948-1957. DOI: 10.1016/S0140-6736(18)32557-1. View

11.

Hofheinz R, Merx K, Haag G, Springfeld C, Ettrich T, Borchert K . FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group. J Clin Oncol. 2022; 40(32):3750-3761. DOI: 10.1200/JCO.22.00380. View

12.

Pietrantonio F, Miceli R, Raimondi A, Kim Y, Kang W, Langley R . Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 2019; 37(35):3392-3400. DOI: 10.1200/JCO.19.01124. View

13.

Andre T, Tougeron D, Piessen G, De La Fouchardiere C, Louvet C, Adenis A . Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. J Clin Oncol. 2022; 41(2):255-265. PMC: 9839243. DOI: 10.1200/JCO.22.00686. View

14.

Smyth E, Nilsson M, Grabsch H, van Grieken N, Lordick F . Gastric cancer. Lancet. 2020; 396(10251):635-648. DOI: 10.1016/S0140-6736(20)31288-5. View

15.

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F . Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36-46. DOI: 10.1056/NEJMoa073149. View

16.

Okines A, Norman A, McCloud P, Kang Y, Cunningham D . Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009; 20(9):1529-1534. DOI: 10.1093/annonc/mdp047. View

17.

Cassidy J, Saltz L, Twelves C, Van Cutsem E, Hoff P, Kang Y . Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. Ann Oncol. 2011; 22(12):2604-2609. DOI: 10.1093/annonc/mdr031. View

18.

Ajani J, Abramov M, Bondarenko I, Shparyk Y, Gorbunova V, Hontsa A . A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer. Ann Oncol. 2017; 28(9):2142-2148. DOI: 10.1093/annonc/mdx275. View

19.

Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M . S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9(3):215-21. DOI: 10.1016/S1470-2045(08)70035-4. View

20.

Hall P, Swinson D, Cairns D, Waters J, Petty R, Allmark C . Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021; 7(6):869-877. PMC: 8120440. DOI: 10.1001/jamaoncol.2021.0848. View